(Q26996579)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S. Vincent Rajkumar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Rafael Fonseca

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Nelson Leung

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

10

Morie A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

19

Suzanne R Hayman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

14

Steven R Zeldenrust

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

7

Prashant Kapoor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

17

Francis Buadi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

12

John A Lust

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

11

Martha Q Lacy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

23

Shaji K Kumar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

18

David Dingli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

13

Stephen J Russell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

5

Robert A Kyle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

3

Asher Chanan-Khan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

8

P Leif Bergsagel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

9

Arleigh McCurdy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

15

Craig Reeder

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

16

Vivek Roy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

22

Joseph Mikhael

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

A Keith Stewart

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Yi Lin

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

1 reference

19 December 2013

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

122

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

26

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

4172-4181

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

2 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Prevention of progression in monoclonal gammopathy of undetermined significance

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Total cost comparison in relapsed/refractory multiple myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Imaging of multiple myeloma and related plasma cell dyscrasias

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Lenalidomide after stem-cell transplantation for multiple myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Improved survival in multiple myeloma and the impact of novel therapies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

International staging system for multiple myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Thalidomide for previously untreated indolent or smoldering multiple myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Multiple myeloma and acute leukemia associated with alkylating agents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Magnetic resonance imaging of the spine in plasma cell dyscrasias. A review

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings. Myélome-Midi-Pyrénées Group.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Contrast enhanced MRI and ¹⁸F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Diagnosis of smoldering multiple myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Survival and years of life lost in different age cohorts of patients with multiple myeloma.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Recent major improvement in long-term survival of younger patients with multiple myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Multiple myeloma and acute myelomonocytic leukemia

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3952477

Treatment of multiple myeloma

28 November 2018

1 reference

12 December 2020

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

1 reference

12 December 2020

Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form

1 reference

12 December 2020

Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients

1 reference

12 December 2020

FDG-PET in the evaluation of myeloma in 2012

1 reference

12 December 2020

Smoldering multiple myeloma: natural history and recognition of an evolving type

1 reference

12 December 2020

Smoldering multiple myeloma

1 reference

12 December 2020

Localized and indolent myeloma

1 reference

12 December 2020

Chemotherapy of myeloma: drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma

1 reference

12 December 2020

Prognosis of asymptomatic multiple myeloma

1 reference

12 December 2020

Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II

1 reference

12 December 2020

Risk of disease progression in asymptomatic multiple myeloma

1 reference

12 December 2020

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

12 December 2020

Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma

1 reference

12 December 2020

Contribution of cytogenetics and in situ hybridization to the study of monoclonal gammopathies of undetermined significance

1 reference

12 December 2020

Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma

1 reference

12 December 2020

Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)

1 reference

12 December 2020

Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma

1 reference

12 December 2020

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

1 reference

12 December 2020

Prognostic features of asymptomatic multiple myeloma

1 reference

12 December 2020

Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma

1 reference

12 December 2020

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma

1 reference

12 December 2020

Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma

1 reference

12 December 2020

Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

1 reference

12 December 2020

10.1182/BLOOD-2013-08-520890

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

release_nzekh2ik3vcutkdigf3gdsvhuy

2 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nzekh2ik3vcutkdigf3gdsvhuy

24 November 2022

mapped directly with Wikidata item

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

PubMed publication ID

24144641

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144641%20AND%20SRC:MED&resulttype=core&format=json